List of Excipients in Branded Drug EFFACLAR

« Back to Dashboard

Generic Drugs Containing EFFACLAR

Company	Ingredient	NDC	Excipient
L’Oreal USA Products Inc	adapalene	49967-591	CARBOMER HOMOPOLYMER TYPE C
L’Oreal USA Products Inc	adapalene	49967-591	EDETATE DISODIUM
L’Oreal USA Products Inc	adapalene	49967-591	METHYLPARABEN
L’Oreal USA Products Inc	adapalene	49967-591	POLOXAMER 182
L’Oreal USA Products Inc	adapalene	49967-591	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in EFFACLAR?

# Of NDCs	Excipient
2	CARBOMER HOMOPOLYMER TYPE C
2	EDETATE DISODIUM
1	METHYLPARABEN
1	PHENOXYETHANOL
2	POLOXAMER 182

Effaclar Excipient Strategy and Commercial Opportunities in Acne and Dermatology Products

Last updated: September 29, 2026

Effaclar is a La Roche-Posay skincare and acne-treatment portfolio owned by L'Oréal, not a single pharmaceutical drug. Its commercial value comes from combining OTC acne actives, cosmetic skin-barrier products, cleanser systems, tolerability claims, and dermatologist distribution. The strongest excipient opportunities are in low-irritancy vehicles, sensory differentiation, preservation, barrier support, and scalable delivery systems for benzoyl peroxide, salicylic acid, adapalene, and cosmetic actives.

What is Effaclar and how is the portfolio regulated?

Effaclar products are marketed under different regulatory classifications depending on the country, product, and active ingredient.

Product category	Representative active or positioning	Typical regulatory status
Medicated acne cleanser	Salicylic acid	OTC drug in the United States when marketed for acne
Benzoyl peroxide treatment	Benzoyl peroxide	OTC acne drug in the United States
Adapalene treatment	Adapalene 0.1%	OTC acne drug in the United States
Effaclar Duo-type products	Salicylic acid, LHA, niacinamide, soothing and barrier ingredients, depending on market	Cosmetic or cosmetic-drug combination depending on jurisdiction
Purifying cleanser	Zinc, thermal water, surfactants and cosmetic ingredients, depending on formulation	Cosmetic or OTC drug depending on claims and active concentration
Moisturizer and corrective products	Niacinamide, glycerin, ceramides, dimethicone and other skin-conditioning ingredients	Cosmetic

The U.S. Food and Drug Administration regulates acne products under the OTC acne monograph framework. Permitted active ingredients include benzoyl peroxide, salicylic acid, and sulfur at specified concentrations and conditions of use. Adapalene 0.1% was approved for nonprescription use in 2016 and is marketed as an OTC acne active.[1,2]

Effaclar products that make acne-treatment claims may be subject to drug-labeling, manufacturing, adverse-event, and monograph requirements. Products positioned only for cleansing, hydration, oil control, or appearance generally fall within cosmetic requirements, provided their claims do not establish drug intended use.

What excipients are strategically important in Effaclar formulations?

Effaclar's excipient strategy is built around efficacy, tolerability, stability, sensory performance, and compatibility with acne-prone skin.

Surfactants and cleansing systems

Cleansers must remove sebum, particulate matter, sunscreen, and makeup without excessive disruption of the stratum corneum. The key formulation choices include:

• Mild anionic surfactants
• Amphoteric surfactants such as betaines
• Nonionic co-surfactants
• Sulfate-free or reduced-sulfate systems
• Low-residue rinsing agents
• Chelators and pH adjusters

A cleanser that removes too much lipid can increase dryness, stinging, and treatment discontinuation. This creates commercial value for mild surfactant systems that preserve cleansing performance while reducing tightness after washing.

For Effaclar, the opportunity is not simply to reduce surfactant strength. It is to develop systems with controlled foam, fast rinse-off, low eye sting, and compatibility with salicylic acid or other acne actives.

Solubilizers and emulsion stabilizers

Many acne and dermatology formulas contain poorly water-soluble ingredients, including certain lipophilic actives, fragrances, emollients, and preservatives. Solubilizers and emulsifiers determine whether the product remains uniform during storage and application.

Relevant excipient classes include:

• Glycols and polyols
• Polysorbates and related solubilizers
• Acrylate-based rheology modifiers
• Carbomers
• Hydrogenated and synthetic emollients
• Glyceryl esters
• Lamellar emulsifiers
• Silicone-based spreading agents

The commercial objective is to deliver active ingredients without a greasy, tacky, or chalky finish. This is especially important for products used on the face, where cosmetic elegance affects repeat purchase.

Humectants and barrier-support ingredients

Humectants reduce dryness and improve after-feel. Common choices include glycerin, propanediol, butylene glycol, pentylene glycol, and hyaluronic acid derivatives.

Barrier-support systems may include:

• Ceramides
• Niacinamide
• Panthenol
• Dimethicone
• Squalane
• Fatty alcohols
• Cholesterol and related lipid systems
• Thermal water or mineral-containing aqueous phases

These ingredients are commercially important because acne consumers often use multiple irritating products. A formulation that supports barrier comfort can extend treatment persistence and reduce switching to competing brands.

Preservatives and preservation boosters

Water-rich gels, cleansers, and emulsions require microbial control. Formulators may use:

• Phenoxyethanol
• Organic acids and their salts
• Benzyl alcohol
• Caprylyl glycol
• Ethylhexylglycerin
• Chelating agents
• pH control

Preservative systems must work across the formulation's pH range and remain compatible with acne actives. The commercial opportunity is to use low-sensitization systems with robust challenge-test performance and limited impact on odor or skin feel.

What formulation opportunities exist for benzoyl peroxide products?

Benzoyl peroxide is chemically reactive and can degrade under unfavorable conditions. The principal excipient and packaging challenges are stability, discoloration, odor, skin irritation, and uniform dosing.

High-value benzoyl peroxide formulation approaches

1. Micronized benzoyl peroxide can improve dispersion and application uniformity.
2. Controlled-release systems can reduce peak irritation while maintaining antimicrobial activity.
3. Polymer or silicone suspending systems can limit settling.
4. Anhydrous or low-water systems may improve chemical stability.
5. Chelators and oxygen-management strategies may reduce degradation pathways.
6. Opaque, air-limited packaging can reduce exposure to light and oxygen.
7. Low-residue vehicles can address whitening and fabric discoloration.

Benzoyl peroxide products also create a packaging opportunity. Airless pumps, laminated tubes, and metered-dose dispensers can improve dose consistency and reduce contamination. Packaging is part of the product's stability architecture rather than a separate commercial feature.

What formulation opportunities exist for salicylic acid and adapalene?

Salicylic acid

Salicylic acid is weakly water-soluble. Its performance depends on pH, solvent selection, concentration, and crystallization control.

Key formulation variables include:

• Hydroalcoholic versus aqueous vehicles
• Glycol-based solvent systems
• pH buffering
• Crystal-growth suppression
• Gel viscosity
• Rinse-off versus leave-on delivery
• Compatibility with niacinamide and other actives

Leave-on products require careful control of irritation. A lower-irritancy vehicle can support higher adherence, especially when consumers combine salicylic acid with retinoids or benzoyl peroxide.

Adapalene

Adapalene is highly lipophilic and commonly delivered in a topical gel. The excipient system must support uniform dispersion, dose reproducibility, chemical stability, and tolerability.

Potential differentiation areas include:

• Improved particle-size control
• More uniform topical distribution
• Reduced residue
• Lower initial irritation
• Compatibility with moisturizers and barrier-support ingredients
• Packaging that limits contamination and maintains dose consistency

Because adapalene is an established OTC active, formulation and delivery differentiation are more commercially realistic than new chemical-entity exclusivity.

What patents protect Effaclar products?

No single patent estate covers the Effaclar brand as a whole. Effaclar is a portfolio of cosmetic and OTC products with market-specific formulations.

The relevant intellectual-property categories are:

IP category	Relevance to Effaclar
Trademarks	High. Effaclar and related product names support brand exclusivity
Trade dress	Potentially relevant to packaging and product presentation
Formulation patents	Potentially relevant to specific compositions or delivery systems
Manufacturing know-how	High, especially for stability, dispersion, preservation, and sensory performance
Method-of-use patents	Limited for conventional acne actives; potentially relevant to specific combinations or indications
Packaging patents	Potentially relevant to airless, metered, or stability-protective systems
Regulatory exclusivity	Relevant only to drug products and specific regulatory pathways

A public patent analysis should be conducted product-by-product and jurisdiction-by-jurisdiction. A single Effaclar patent number, expiration date, or Orange Book listing cannot be assigned to the brand without identifying the exact product, formulation, country, and legal entity.

What is the Orange Book status of Effaclar?

Effaclar is not a single Orange Book-listed drug. Cosmetic Effaclar products are not expected to appear in the FDA Orange Book. U.S. OTC acne products may be marketed under the applicable OTC monograph framework rather than through a conventional new drug application with an Orange Book reference listing.

The Orange Book is therefore a limited tool for assessing Effaclar competition. A complete competitive review should also examine:

• FDA Drug Establishment and product information
• OTC monograph compliance
• Drug Facts labeling
• National Drug Code records where applicable
• U.S. trademark registrations
• Published formulation and manufacturing patents
• European Union cosmetic ingredient and claims requirements

When does Effaclar lose exclusivity?

Effaclar does not have one portfolio-wide patent expiration date. Exclusivity depends on the product type.

Product type	Main protection mechanism	Loss-of-exclusivity pattern
Cosmetic cleanser	Trademark, formulation know-how, distribution, brand	No statutory patent cliff unless a specific patent applies
Cosmetic corrective cream	Brand, claims, formulation know-how, trade dress	Competitive erosion occurs through imitation and retailer substitution
Salicylic acid OTC product	Monograph compliance, brand, formulation and packaging differentiation	Generic-style competition is possible without a traditional patent challenge
Benzoyl peroxide OTC product	Monograph compliance, formulation, packaging, brand	Competition can enter through alternative formulations and brands
Adapalene OTC product	Active-ingredient history, formulation, labeling, brand	Substitution risk is driven by approved or monograph-compliant topical products

For cosmetic products, the practical exclusivity period is determined by consumer recognition, dermatologist recommendation, retailer placement, formulation quality, and marketing investment. Those factors can remain commercially relevant after formulation patents expire.

Which companies compete with Effaclar?

Effaclar competes across several overlapping segments rather than against one product.

Competitor	Core strength	Competitive overlap
CeraVe	Barrier repair, ceramides, dermatologist positioning	Cleansers, moisturizers, acne products
Neutrogena	Mass-market acne recognition	Salicylic acid and benzoyl peroxide
Differin	Adapalene and acne-treatment credibility	Retinoid treatment
PanOxyl	High-strength benzoyl peroxide	Acne wash and treatment
Avène	Sensitive-skin and pharmacy positioning	Dermatology skincare
Bioderma	Sebium acne and oily-skin range	Cleansers and corrective products
Eucerin	Dermatology and sensitive-skin positioning	Acne and barrier-care products
The Ordinary	Low-price active-ingredient products	Acid and niacinamide products
Private-label retailers	Price and convenience	Basic cleansers and acne treatments

Effaclar's strongest differentiator is the combination of pharmacy-channel credibility, dermatology positioning, and a broad regimen architecture. Its vulnerability is price competition from CeraVe, private-label products, and direct-to-consumer brands with simpler active-ingredient messaging.

What licensing deals and litigation affect Effaclar?

No major publicly disclosed licensing transaction or litigation matter specific to the Effaclar brand is established in the cited public sources. L'Oréal's broader portfolio includes acquisitions, licenses, and research collaborations, but those transactions should not be treated as Effaclar-specific rights.

Potential disputes would more likely involve:

• Trademark infringement
• False or unsubstantiated acne claims
• Packaging or trade-dress copying
• Patent claims covering a particular topical composition
• Regulatory claims involving drug-versus-cosmetic positioning
• Advertising claims concerning tolerability, efficacy, or dermatologist recommendation

Paragraph IV litigation is generally associated with ANDA applicants challenging patents listed for an approved prescription drug. It is not the primary competitive mechanism for the broader Effaclar cosmetic portfolio.

What commercial opportunities exist for excipient suppliers?

The strongest opportunities are specialized systems that improve performance without requiring a new active ingredient.

Priority opportunity areas

Opportunity	Commercial value
Low-irritancy surfactant blends	Supports daily use and sensitive-skin positioning
Stable benzoyl peroxide dispersions	Addresses degradation, settling, and irritation
Adapalene gel vehicles	Improves spreadability, residue, and tolerability
Salicylic acid solubilization systems	Enables clear, stable, lower-irritancy products
Barrier-support emulsions	Supports combination use with acne drugs
Airless and metered packaging	Improves stability, hygiene, and dose consistency
Silicone and lamellar delivery systems	Improves skin feel and consumer adherence
Preservative-boosting systems	Helps reduce conventional preservative load
Sustainable excipients	Supports environmental claims and retailer requirements
Pediatric and sensitive-skin vehicles	Expands use among younger and irritation-prone consumers

Suppliers with the strongest commercial position will offer complete formulation platforms, not isolated ingredients. A platform that combines excipient selection, stability data, sensory testing, scale-up support, and regulatory documentation is more valuable to a global dermatology brand than a commodity humectant or thickener.

How strong is the Effaclar commercial and IP position?

Effaclar has a strong brand and channel position but a fragmented legal exclusivity profile.

Dimension	Assessment
Brand strength	High
Dermatologist and pharmacy positioning	High
Formulation differentiation	Moderate to high by product
Patent-based exclusivity	Product-specific and not established at portfolio level
Orange Book protection	Not applicable to the brand as a whole
Generic entry risk	Moderate for conventional OTC actives
Private-label substitution risk	High for basic cleansers and moisturizers
Manufacturing barrier	Moderate, rising for stable active delivery and sensory quality
Pricing power	Moderate to high in pharmacy and premium skincare channels
Global scalability	High, subject to market-specific claims and formulas

Revenue exposure for Effaclar is not separately disclosed by L'Oréal. The brand contributes to the Dermatological Beauty division, which includes La Roche-Posay, CeraVe, SkinCeuticals, Vichy, and other brands. Public company reporting does not provide a standalone Effaclar revenue figure.[3]

Key Takeaways

• Effaclar is a La Roche-Posay skincare and acne-treatment portfolio, not a single pharmaceutical drug.
• Its excipient strategy centers on tolerability, active stability, sensory performance, preservation, and barrier support.
• Benzoyl peroxide, salicylic acid, and adapalene create different delivery and stability problems.
• The brand does not have one portfolio-wide patent expiration date or Orange Book position.
• Trademark, formulation know-how, packaging, dermatologist distribution, and retailer access are more important than a single patent for many Effaclar products.
• Excipient suppliers have the clearest opportunities in low-irritancy surfactants, stable active dispersions, barrier emulsions, airless packaging, and complete delivery platforms.
• Competitive risk is highest from CeraVe, Neutrogena, Differin, PanOxyl, Avène, Bioderma, and private-label acne products.

FAQs

Is Effaclar a prescription drug?

No. Effaclar includes cosmetic products and OTC acne products. Regulatory status depends on the product, active ingredient, claims, and market.

Does Effaclar contain salicylic acid?

Some Effaclar products contain salicylic acid or related exfoliating ingredients, but the formula differs by product and country.

Can a generic company copy Effaclar?

A company may develop a competing OTC or cosmetic product using similar permitted ingredients, subject to regulatory, trademark, labeling, formulation, and unfair-competition requirements.

Are Effaclar formulations patent-protected?

Some individual compositions, delivery systems, or manufacturing processes may be patentable. The Effaclar brand itself is primarily protected through trademarks, know-how, distribution, and product-specific rights.

Who owns Effaclar?

Effaclar is a La Roche-Posay brand within L'Oréal's Dermatological Beauty business.

References

1. U.S. Food and Drug Administration. (2021). Acne products containing benzoyl peroxide, salicylic acid, and sulfur: Over-the-counter drug monograph framework. FDA.

2. U.S. Food and Drug Administration. (2016). FDA approves first over-the-counter adapalene gel to treat acne. FDA.

3. L'Oréal. (2024). Universal registration document and annual financial report. L'Oréal S.A.